Table 5.
Country | Ciprofloxacin | Co‐amoxiclav | Erythromycin | Gentamicin | Tetracyclines | Method used | Quantitative (Q) or categorical (SIR) | Interpretive criteria |
---|---|---|---|---|---|---|---|---|
Austria | ● | ● | ● | ● | DL | Q | Interpreted by ECDC. EUCAST ECOFF (CIP, ERY, GEN, TET), CA‐SFM CBP 2016 (AMC) | |
Cyprus | ● | ● | ● | DD | Q | Interpreted by ECDC, as for Austria | ||
Denmark | ● | ● | ● | ● | DL | Q | Interpreted by ECDC, as for Austria | |
Estonia | ● | ● | ● | DD | Q | Interpreted by ECDC, as for Austria | ||
Finland | ● | ● | ● | DD/DLG | Q | Interpreted by ECDC, as for Austria | ||
France | ● | ● | ● | ● | ● | DD | SIR | EUCAST CBP 2016 (CIP, ERY, TET), CA‐SFM CBP 2016 (AMC, GEN) |
Iceland | ● | ● | DD/DLG | SIR | EUCAST CBP 2016 | |||
Italy | ● | ● | ● | ● | DD | Q | Interpreted by ECDC, as for Austria | |
Lithuania | ● | ● | ● | DD | SIR | EUCAST CBP 2016 | ||
Luxembourg | ● | ● | ● | ● | DD/DLG | Q | Interpreted by ECDC, as for Austria | |
Malta | ● | ● | DLG/DD | Q | Interpreted by ECDC, as for Austria | |||
Netherlands | ● | ● | ● | DD/DL | SIR | Survey in 12 clinical labs in the Netherlands in 2009 (Ned Tijdschr Med Microbiol 2009;17:nr1) | ||
Norway | ● | ● | ● | ● | DLG | Q | Interpreted by ECDC, as for Austria | |
Portugal | ● | ● | ● | ● | DD | Q | Interpreted by ECDC, as for Austria | |
Romania | ● | ● | ● | ● | ● | DD | Q | Interpreted by ECDC, as for Austria |
Slovakia | ● | ● | ● | ● | ● | DL | SIR | In 2013, CLSI CB |
Slovenia | ● | ● | ● | DD | Q | Interpreted by ECDC, as for Austria | ||
Spain | ● | ● | ● | ● | DLG | Q | Interpreted by ECDC, as for Austria | |
United Kingdom | ● | ● | ● | ● | DD/DL/DLG | SIR | Varies depending on clinical microbiology laboratory |
AST: antimicrobial susceptibility testing; CA‐SFM: French Society for Microbiology; CBP: clinical breakpoint; DD: disk diffusion; DL: dilution; DLG: dilution with gradient strip; ECDC: European Centre for Disease Prevention and Control; ECOFF: epidemiological cut‐off; EUCAST: European Committee on Antimicrobial Susceptibility Testing; Q: quantitative data; SIR: susceptible, intermediate, resistant (categorical data). AMC: amoxicillin/clavulanate; CIP: ciprofloxacin; ERY: erythromycin; GEN: gentamicin; TET: tetracycline.